This company has been marked as potentially delisted and may not be actively trading. Oncobiologics (ONS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ONS vs. CADL, DNA, TSHA, TECX, GLUE, ALLO, SLDB, AURA, ATYR, and CMPXShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Candel Therapeutics (CADL), Ginkgo Bioworks (DNA), Taysha Gene Therapies (TSHA), Tectonic Therapeutic (TECX), Monte Rosa Therapeutics (GLUE), Allogene Therapeutics (ALLO), Solid Biosciences (SLDB), Aura Biosciences (AURA), Atyr PHARMA (ATYR), and Compass Therapeutics (CMPX). These companies are all part of the "medical" sector. Oncobiologics vs. Candel Therapeutics Ginkgo Bioworks Taysha Gene Therapies Tectonic Therapeutic Monte Rosa Therapeutics Allogene Therapeutics Solid Biosciences Aura Biosciences Atyr PHARMA Compass Therapeutics Candel Therapeutics (NASDAQ:CADL) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends. Is CADL or ONS more profitable? Candel Therapeutics has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -629.29% -173.39% Oncobiologics -464.47%N/A -93.28% Does the MarketBeat Community prefer CADL or ONS? Oncobiologics received 158 more outperform votes than Candel Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Candel Therapeutics an outperform vote while only 63.74% of users gave Oncobiologics an outperform vote. CompanyUnderperformOutperformCandel TherapeuticsOutperform Votes1666.67% Underperform Votes833.33% OncobiologicsOutperform Votes17463.74% Underperform Votes9936.26% Which has stronger earnings & valuation, CADL or ONS? Candel Therapeutics has higher earnings, but lower revenue than Oncobiologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel Therapeutics$120K2,192.49-$37.94M-$1.75-3.18Oncobiologics$3.81M23.12-$38.84MN/AN/A Does the media prefer CADL or ONS? In the previous week, Candel Therapeutics had 7 more articles in the media than Oncobiologics. MarketBeat recorded 7 mentions for Candel Therapeutics and 0 mentions for Oncobiologics. Candel Therapeutics' average media sentiment score of 0.19 beat Oncobiologics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Candel Therapeutics Neutral Oncobiologics Neutral Do institutionals and insiders hold more shares of CADL or ONS? 13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Oncobiologics shares are held by institutional investors. 41.6% of Candel Therapeutics shares are held by company insiders. Comparatively, 11.5% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, CADL or ONS? Candel Therapeutics has a beta of -1.29, suggesting that its stock price is 229% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Do analysts prefer CADL or ONS? Candel Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 277.02%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Candel Therapeutics is more favorable than Oncobiologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Oncobiologics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCandel Therapeutics beats Oncobiologics on 11 of the 16 factors compared between the two stocks. Remove Ads Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONS vs. The Competition Export to ExcelMetricOncobiologicsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$88.08M$2.93B$5.54B$7.86BDividend YieldN/A1.55%5.35%4.06%P/E RatioN/A30.1423.4418.67Price / Sales23.12396.77367.8787.31Price / CashN/A168.6838.1634.64Price / Book-0.903.656.634.09Net Income-$38.84M-$71.95M$3.20B$246.93M Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONSOncobiologicsN/A$1.22-7.6%N/A-88.9%$88.08M$3.81M0.00N/AGap DownHigh Trading VolumeCADLCandel Therapeutics2.3114 of 5 stars$7.50-8.8%$21.00+180.0%+257.6%$388.27M$120,000.00-4.3460DNAGinkgo Bioworks0.5464 of 5 stars$6.67-6.4%$4.58-31.4%N/A$386.80M$227.04M-0.51640Positive NewsTSHATaysha Gene Therapies2.7322 of 5 stars$1.80+1.7%$6.63+268.1%-51.6%$369.00M$8.33M2.86180News CoveragePositive NewsGap UpTECXTectonic Therapeutic3.1242 of 5 stars$19.01-10.4%$77.75+309.0%N/A$354.78MN/A-3.23120High Trading VolumeGLUEMonte Rosa Therapeutics3.2236 of 5 stars$5.49-3.2%$15.50+182.3%-34.2%$348.76M$75.62M-3.0090Short Interest ↓Positive NewsALLOAllogene Therapeutics3.0274 of 5 stars$1.57-1.9%$9.29+491.6%-67.3%$341.11M$22,000.00-1.01310Gap UpSLDBSolid Biosciences3.3827 of 5 stars$4.26-5.1%$15.67+267.8%-72.2%$330.12M$8.09M-1.40100Positive NewsAURAAura Biosciences2.3449 of 5 stars$5.99-15.4%$23.00+284.0%-25.4%$299.21MN/A-3.4650High Trading VolumeATYRAtyr PHARMA2.7407 of 5 stars$3.24-7.2%$18.60+474.1%N/A$287.90M$235,000.00-3.4553Short Interest ↑Gap UpCMPXCompass Therapeutics3.0042 of 5 stars$2.04-5.6%$11.38+457.6%-4.0%$282.10M$850,000.00-5.5120Analyst ForecastOptions VolumeNews Coverage Remove Ads Related Companies and Tools Related Companies CADL Alternatives DNA Alternatives TSHA Alternatives TECX Alternatives GLUE Alternatives ALLO Alternatives SLDB Alternatives AURA Alternatives ATYR Alternatives CMPX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONS) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
